“Receiving FDA clearance to proceed with our Phase IIb study is a significant catalyst for Cereno,” said Sten R. Sörensen, CEO at Cereno Scientific. About Cereno Scientific ABCereno Scientific is pioneering treatments to enhance and extend life. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B).

Source: The Bubble December 09, 2025 10:13 UTC